WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329662

CAS#: 22994-85-0

Description: Benznidazole is an antiparasitic medication used in the treatment of Chagas disease. While it is highly effective in early disease this decreases in those who have long term infection. It is the first line treatment given its moderate side effects compared to nifurtimox. It is taken by mouth. Benznidazole is a nitroimidazole antiparasitic with good activity against acute infection with Trypanosoma cruzi, commonly referred to as Chagas disease. Like other nitroimidazoles, benznidazole's main mechanism of action is to generate radical species which can damage the parasite's DNA or cellular machinery. The mechanism by which nitroimidazoles do this seems to depend on whether or not oxygen is present. This is particularly relevant in the case of Trypanosoma species, which are considered facultative anaerobes.

Price and Availability


USD 250
USD 1050

USD 450

USD 650

Benznidazole, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 329662
Name: Benznidazole
CAS#: 22994-85-0
Chemical Formula: C12H12N4O3
Exact Mass: 260.0909
Molecular Weight: 260.253
Elemental Analysis: C, 55.38; H, 4.65; N, 21.53; O, 18.44

Synonym: Benznidazole; NSC 299972; Radanil; Ro 07-1051; Ro 71051.

IUPAC/Chemical Name: 2-Nitro-N-(phenylmethyl)-1H-imidazole-1-acetamide


InChi Code: InChI=1S/C12H12N4O3/c17-11(14-8-10-4-2-1-3-5-10)9-15-7-6-13-12(15)16(18)19/h1-7H,8-9H2,(H,14,17)

SMILES Code: O=C(NCC1=CC=CC=C1)CN2C=CN=C2[N+]([O-])=O

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Menna-Barreto RF, de Castro SL. Clear Shot at Primary Aim: Susceptibility of Trypanosoma cruzi Organelles, Structures and Molecular Targets to Drug Treatment. Curr Top Med Chem. 2017;17(10):1212-1234. doi: 10.2174/1568026616666161025161858. Review. PubMed PMID: 27784255.

2: Duschak VG. Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period. Recent Pat Antiinfect Drug Discov. 2016;11(2):74-173. doi: 10.2174/1574891X11666161024165304. Review. PubMed PMID: 27784230.

3: Nabavi SF, Sureda A, Daglia M, Izadi M, Rastrelli L, Nabavi SM. Flavonoids and Chagas' Disease: The Story So Far! Curr Top Med Chem. 2017;17(4):460-466. Review. PubMed PMID: 27558676.

4: Rodriguez JB, Falcone BN, Szajnman SH. Detection and treatment of Trypanosoma cruzi: a patent review (2011-2015). Expert Opin Ther Pat. 2016 Sep;26(9):993-1015. doi: 10.1080/13543776.2016.1209487. Epub 2016 Jul 19. Review. PubMed PMID: 27376456.

5: Paucar R, Moreno-Viguri E, Pérez-Silanes S. Challenges in Chagas Disease Drug Discovery: A Review. Curr Med Chem. 2016;23(28):3154-3170. Review. PubMed PMID: 27356544.

6: Briceno L, Mosca W. [What is not searched, it is difficult to find: Chagas' disease]. G Ital Cardiol (Rome). 2016 May;17(5):343-7. doi: 10.1714/2252.24258. Review. Italian. PubMed PMID: 27310907.

7: Salomao K, Menna-Barreto RF, de Castro SL. Stairway to Heaven or Hell? Perspectives and Limitations of Chagas Disease Chemotherapy. Curr Top Med Chem. 2016;16(20):2266-89. Review. PubMed PMID: 27072716.

8: Bermudez J, Davies C, Simonazzi A, Real JP, Palma S. Current drug therapy and pharmaceutical challenges for Chagas disease. Acta Trop. 2016 Apr;156:1-16. doi: 10.1016/j.actatropica.2015.12.017. Epub 2015 Dec 30. Review. PubMed PMID: 26747009.

9: Angheben A, Boix L, Buonfrate D, Gobbi F, Bisoffi Z, Pupella S, Gandini G, Aprili G. Chagas disease and transfusion medicine: a perspective from non-endemic countries. Blood Transfus. 2015 Oct;13(4):540-50. doi: 10.2450/2015.0040-15. Review. PubMed PMID: 26513769; PubMed Central PMCID: PMC4624528.

10: Tanowitz HB, Machado FS, Spray DC, Friedman JM, Weiss OS, Lora JN, Nagajyothi J, Moraes DN, Garg NJ, Nunes MC, Ribeiro AL. Developments in the management of Chagas cardiomyopathy. Expert Rev Cardiovasc Ther. 2015 Dec;13(12):1393-409. doi: 10.1586/14779072.2015.1103648. Epub 2015 Oct 23. Review. PubMed PMID: 26496376; PubMed Central PMCID: PMC4810774.

11: Sguassero Y, Cuesta CB, Roberts KN, Hicks E, Comandé D, Ciapponi A, Sosa-Estani S. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies. PLoS One. 2015 Oct 5;10(10):e0139363. doi: 10.1371/journal.pone.0139363. eCollection 2015. Review. PubMed PMID: 26436678; PubMed Central PMCID: PMC4593559.

12: Malik LH, Singh GD, Amsterdam EA. The Epidemiology, Clinical Manifestations, and Management of Chagas Heart Disease. Clin Cardiol. 2015 Sep;38(9):565-9. doi: 10.1002/clc.22421. Epub 2015 May 21. Review. PubMed PMID: 25993972.

13: Albareda MC, Laucella SA. Modulation of Trypanosoma cruzi-specific T-cell responses after chemotherapy for chronic Chagas disease. Mem Inst Oswaldo Cruz. 2015 May;110(3):414-21. doi: 10.1590/0074-02760140386. Review. PubMed PMID: 25993507; PubMed Central PMCID: PMC4489479.

14: Pinazo MJ, Thomas MC, Bustamante J, Almeida IC, Lopez MC, Gascon J. Biomarkers of therapeutic responses in chronic Chagas disease: state of the art and future perspectives. Mem Inst Oswaldo Cruz. 2015 May;110(3):422-32. doi: 10.1590/0074-02760140435. Epub 2015 Apr 28. Review. PubMed PMID: 25946151; PubMed Central PMCID: PMC4489480.

15: Bellera CL, Sbaraglini ML, Balcazar DE, Fraccaroli L, Vanrell MC, Casassa AF, Labriola CA, Romano PS, Carrillo C, Talevi A. High-throughput drug repositioning for the discovery of new treatments for Chagas disease. Mini Rev Med Chem. 2015;15(3):182-93. Review. PubMed PMID: 25769967.

16: Imai K, Maeda T, Sayama Y, Osa M, Mikita K, Kurane I, Miyahira Y, Kawana A, Miura S. Chronic Chagas disease with advanced cardiac complications in Japan: Case report and literature review. Parasitol Int. 2015 Oct;64(5):240-2. doi: 10.1016/j.parint.2015.02.005. Epub 2015 Mar 3. Review. PubMed PMID: 25744336.

17: Keenan M, Chaplin JH. A new era for chagas disease drug discovery? Prog Med Chem. 2015;54:185-230. doi: 10.1016/bs.pmch.2014.12.001. Epub 2015 Jan 17. Review. PubMed PMID: 25727705.

18: Morilla MJ, Romero EL. Nanomedicines against Chagas disease: an update on therapeutics, prophylaxis and diagnosis. Nanomedicine (Lond). 2015 Feb;10(3):465-81. doi: 10.2217/nnm.14.185. Review. PubMed PMID: 25707979.

19: Alonso-Padilla J, Rodríguez A. High throughput screening for anti-Trypanosoma cruzi drug discovery. PLoS Negl Trop Dis. 2014 Dec 4;8(12):e3259. doi: 10.1371/journal.pntd.0003259. eCollection 2014 Dec. Review. PubMed PMID: 25474364; PubMed Central PMCID: PMC4256210.

20: Urbina JA. Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives. J Eukaryot Microbiol. 2015 Jan-Feb;62(1):149-56. doi: 10.1111/jeu.12184. Epub 2014 Nov 13. Review. PubMed PMID: 25284065.